Skip to main content
BALCHEM CORP logo

BALCHEM CORP — Investor Relations & Filings

Ticker · BCPC ISIN · US0576652004 LEI · 549300VR70OPMHUI3557 US Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2019-05-28 Regulatory Filings
Country US United States of America
Listing US BCPC

About BALCHEM CORP

https://balchem.com/

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products. The company operates through three primary segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health division is a leader in essential nutrients like choline, chelated minerals, and vitamin K2, utilizing advanced microencapsulation technologies for the food and nutritional supplement markets. The Animal Nutrition & Health segment provides a portfolio of products to meet the nutritional needs of animals, with a key position in choline chloride. The Specialty Products segment includes Performance Gases for various industrial applications and Plant Nutrition solutions. Balchem is focused on delivering innovative, science-based solutions to improve health and nutrition.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically details the completion of an acquisition (Item 2.01) of Chemogas by Balchem Corporation, including purchase price, financing, and closing date. It also includes a press release about the closing (Item 7.01) and references exhibits related to the acquisition agreement. There are no financial statements or detailed financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy, earnings release, or management discussion. It is a regulatory filing announcing a material event (acquisition completion). Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7261 characters) and content confirm it is a full 8-K report, not just a brief announcement or certification. Confidence is high due to clear identification of the form and content.
2019-05-28 English
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 2, 2019, reporting the entry into a material definitive agreement for the acquisition of Chemogas Holding NV by Balchem Corporation. It includes a summary of the Securities Purchase Agreement, details of the acquisition terms, and a press release. The document is a current report disclosing a significant transaction (an acquisition) rather than a full annual or quarterly report, earnings release, or other types of filings. The primary content is about the acquisition agreement and related disclosures, which fits the category of M&A Activity filings. The document length is over 12,000 characters, indicating it is not a brief announcement but a substantive filing. Therefore, the appropriate classification is M&A Activity (Code: TAR).
2019-05-06 English
FORM 10-Q
Interim / Quarterly Report Q1 2019
2019-05-03 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 3, 2019, reporting earnings for the first quarter ended March 31, 2019. It includes a press release as Exhibit 99.1 that reports financial results for the quarter. The text explicitly states it is a current report and the content is a press release announcing quarterly financial results. The document length is 3292 characters, which is relatively short and primarily contains the announcement and the press release, not a full detailed financial report. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. Therefore, the correct classification is ER with high confidence.
2019-05-03 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A, which is a definitive proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document explicitly states it is a 'Definitive Proxy Statement' and includes typical proxy filing details such as fee payment information and filing party. The document length is short (1983 characters), consistent with a proxy statement rather than a full report. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2019-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-29 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.